FDA Panel Struggles to Agree on Effectiveness of Tumor Device

Devices & Diagnostics Letter
A A
An FDA advisory panel reached deadlock over the effectiveness of a novel device that blasts glioblastoma multiforme (GBM) brain tumors with an electrical field, with the panel chair breaking the tie in favor of the device.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00